Confidential once completed

Please answer <u>all the questions</u>

<mark>()</mark>

ECUSTEC Initial Admission for Trial Treatment Form

TO BE COMPLETED AT DISCHARGE FROM INITIAL HOSPITAL ADMISSION FOR TRIAL TREATMENT OR UPTO DAY 56, WHICHEVER IS SOONEST						
Trial Number:	Site Name:	Date of Bir	rth:	/	(mon/yyyy)	
Part A: Assessment Details	6					
Date of Admission: (dd/mon/yyy	(y) Date of	Discharge: (dd/mon/yy	уу)			
Has the patient died?	Yes No				died, or is unwilling e complete the	
Has the patient/parent confirmed willingness to continue? Yes No ECUSTEC Exit Form.						
Location of Patient During Adm	ission (put "0" if patient did	not stay on the relevant ward ty	ype, record	d stay episode	es on separate lines)	
General Ward (Stay 1)	Days on ward	Start Date: (dd/mon/y	ууу)	Stop Date	: (dd/mon/yyyy)	
General Ward (Stay 2)	Days on ward	Start Date: (dd/mon/y	ууу)	Stop Date	: (dd/mon/yyyy)	
PICU (Stay 1)	Days on ward	Start Date: (dd/mon/y	ууу)	Stop Date	: (dd/mon/yyyy)	
PICU (Stay 2)	Days on ward	Start Date: (dd/mon/y	уууу)	Stop Date	(dd/mon/yyyy)	
HDU (Stay 1)	Du (Stay 1) Days on ward Start Date: (dd/mon/yyyy) Stop Date: (dd/mon/yyyy)					
HDU (Stay 2)	Days on ward	Start Date: (dd/mon/yyyy) Stop Date: (dd/mon/yyyy)				
Theatre Visit No. of Visits Procedures:						
Part B: Vaccinations						
Yes* No *If yes, Date						
Has the patient received conjugate meningococcal ACWY vaccine (Nimenrix or Menveo)?						
Has the patient received Meningococcal B vaccine (Bexsero [™]) as part of the UK immunisation programme? (dd/mon/yyyy)						
Has the patient received Meningococcal B vaccine (Bexsero™) as part of the ECUSTEC trial? (dd/mon/yyyy)						
Part C: Signs and Symptoms for Meningococcal Disease and Septicaemia						
Has the patient had signs or symptoms for meningococcal disease and/or septicaemia? Yes No						
Are parents/patient/guardian in possession of the ECUSTEC Meningitis Warning Card and ECUSTEC Patient Study Card?						
Part D: Protocol-mandated	Therapy					
Has trial-mandated antibiotic cover	for 2 weeks post-discha	rge been supplied?	Yes	s 🗌 No	Not Applicable	
Has antibiotic cover by the GP bee	en confirmed, in line with	the ECUSTEC Initial GP	Letter?	s 🗌 No	Not Applicable	

Confidential once completed

Please answer <u>all the questions</u>

1	6	
	0	

Trial Number:	Date of Birth: / (mon/yyyy
Part E: Infection Status for Grade ≥ 3 (During th	

Has the patient had a severe wound infection? *If yes, how many?	Yes* No				
Has the patient had a severe vascular catheter infection? *If yes, how many?	Yes* No				
Has the patient had a severe episode of peritonitis? *If yes, how many?	Yes* No				
Has the patient had any other severe infections? *If yes to "other", please state:	Yes* No				
 If the patient has experienced an event which: Is fatal Or life-threatening Caused either admission to hospital or prolongation of a hospital stay Resulted in persistent or significant disability or incapacity Resulted in a congenital anomaly/birth defect Please complete the ECUSTEC Serious Adverse Event (SAE) Form. 					

Confidential once completed

Please answer all the questions

1			-	
(9	2)	
			2	

Trial Number:	Date of Birth: / (mon/yyyy)

Part F: Laboratory Readings

Bloods and Biochemistry (To be completed from the case notes. Please state whether there were abnormal readings between baseline (<u>not</u> including values reported on the baseline form) and discharge/day 56, whichever is soonest for the parameters below.)


1 /					
Parameter	 Raised *If raised, peak eading reading * No		Date of Peak	Ongoing Yes No	Date returned to normal range (if applicable)
White blood cell count		. 10 ⁹ /L	(dd/mon/yyyy)		(dd/mon/yyyy)
Urea		mmol/L	(dd/mon/yyyy)		(dd/mon/yyyy)
			Date of Onset of abnormal range		Date of Resolution
Lactose Dehydrogenase (LDH)		U/L	(dd/mon/yyyy)		(dd/mon/yyyy)
C-reactive Protein		mg/L	(dd/mon/yyyy)		(dd/mon/yyyy)

Regular Laboratory Readings (Please complete daily laboratory readings for neutrophil cell count, platelets and sodium, up until discharge or day 14, which ever is soonest. If still in hospital after day 14 and resolution has not occurred, weekly readings should be collected.)

Regular Neutrophil Cell Count (Day 1 is prior to trial drug administration and is recorded on the Baseline Form)

Day	Recorded? Yes No	Date of Reading	Neutrophil Cell Count	Outside norr Yes	nal range? No
2		(dd/mon/yyyy)	. 10 ⁹ /L		
3		(dd/mon/yyyy)	. 10 ⁹ /L		
4		(dd/mon/yyyy)	. 10 ⁹ /L		
5		(dd/mon/yyyy)	. 10 ⁹ /L		
6		(dd/mon/yyyy)	. 10 ⁹ /L		
7		(dd/mon/yyyy)	. 10 ⁹ /L		
8		(dd/mon/yyyy)	. 10 ⁹ /L		
9		(dd/mon/yyyy)	. 10 ⁹ /L		
10		(dd/mon/yyyy)	. 10 ⁹ /L		
11		(dd/mon/yyyy)	. 10 ⁹ /L		
12		(dd/mon/yyyy)	. 10 ⁹ /L		
13		(dd/mon/yyyy)	. 10 ⁹ /L		
14		(dd/mon/yyyy)	. 10 ⁹ /L		
21		(dd/mon/yyyy)	. 10 ⁹ /L		
28		(dd/mon/yyyy)	. 10 ⁹ /L		
35		(dd/mon/yyyy)	. 10 ⁹ /L		
42		(dd/mon/yyyy)	. 10 ⁹ /L		
49		(dd/mon/yyyy)	. 10 ⁹ /L		
56		(dd/mon/yyyy)	. 10 ⁹ /L		
Has the n	eutropenia been	resolved?	Yes* No	Not Applica	ıble
*If yes, pro	ovide the date of re	esolution: (dd/mon/yyyy)		

Date of Birth: ____ / ___ /



Trial Number:

Day	Recorded?		Date of Reading	Platelet Count	Had the pati platelet tran day of readi	sfusion on
	Yes	No			Yes	No
2			(dd/mon/yyyy)	10 ⁹ /L		
3			(dd/mon/yyyy)	10 ⁹ /L		
4			(dd/mon/yyyy)	10 ⁹ /L		
5			(dd/mon/yyyy)	10 ⁹ /L		
6			(dd/mon/yyyy)	10 ⁹ /L		
7			(dd/mon/yyyy)	10 ⁹ /L		
8			(dd/mon/yyyy)	10 ⁹ /L		
9			(dd/mon/yyyy)	10 ⁹ /L		
10			(dd/mon/yyyy)	10 ⁹ /L		
11			(dd/mon/yyyy)	10 ⁹ /L		
12			(dd/mon/yyyy)	10 ⁹ /L		
13			(dd/mon/yyyy)	10 ⁹ /L		
14			(dd/mon/yyyy)	10 ⁹ /L		

Where the patient remains in hospital after day 14 and weekly platelet readings are being recorded, please state the date on which any transfusion occurred in the previous week

Day	Reco Yes	rded No	Date of Reading	Platelet count	Has the patier platelet transf since the prev recorded read Yes*	usion vious	*If yes, Date of Transfusion
21			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)
28			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)
35			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)
42			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)
49			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)
56			(dd/mon/yyyy)	10 ⁹ /L			(dd/mon/yyyy)

Has the thrombocytopenia been resolved?	Yes*	No
*If yes, provide the date of resolution: (dd/mon/yyyy)		

Confidential once completed

Please answer all the questions

	_	
1	0	
L		
6	Cliet	εU/

Trial	Number:	
-------	---------	--

Date of Birth: ____ / ___ (mon/yyyy)

Regular Sodium Readings (Day 1 is prior to trial drug administration and is recorded on the Baseline Form)							
Day	Recorded? Yes No	Date of Reading	Sodium Reading	Outside nor Yes	mal range? No		
2		(dd/mon/yyyy)	mmol/L				
3		(dd/mon/yyyy)	mmol/L				
4		(dd/mon/yyyy)	mmol/L				
5		(dd/mon/yyyy)	mmol/L				
6		(dd/mon/yyyy)	mmol/L				
7		(dd/mon/yyyy)	mmol/L				
8		(dd/mon/yyyy)	mmol/L				
9		(dd/mon/yyyy)	mmol/L				
10		(dd/mon/yyyy)	mmol/L				
11		(dd/mon/yyyy)	mmol/L				
12		(dd/mon/yyyy)	mmol/L				
13		(dd/mon/yyyy)	mmol/L				
14		(dd/mon/yyyy)	mmol/L				
21		(dd/mon/yyyy)	mmol/L				
28		(dd/mon/yyyy)	mmol/L				
35		(dd/mon/yyyy)	mmol/L				
42		(dd/mon/yyyy)	mmol/L				
49		(dd/mon/yyyy)	mmol/L				
56		(dd/mon/yyyy)	mmol/L				
Has any s	odium derangem	ent been resolved?	Yes* No	Not Applic	able		
*If yes, pro	ovide the date of re	esolution: (dd/mon/yyyy)					

Part G: Targeted Concomitant Medications (between randomisation and discharge/day 56, whichever is soonest.)	Yes	No
Anti-hypertensive medication (except ACE inhibitor or Angiotensin Receptor Blocker)		
ACE inhibitor or Angiotensin Receptor Blocker		
Folic Acid		
Alfacaclidol		
Calcium supplement (except Calcium carbonate or acetate)		
Phosphate binder (eg calcium carbonate, calcium acetate, sevelemar)		

Confidential once completed

Please answer all the questions

		_	
/			
	(Č	5	
14	ò.,	-14	-)

Trial Number:			Date	e of Birth: _	/	(mon/yyyy)	
Part H(a): Plasma Exchange and Plasma Infusions (received since 2nd dose of trial treatment and up to discharge/day 56, whichever is soonest.) Note - patients should NOT receive plasma exchange							
Did the patient have a plasma infusion?		Yes*	No)			
*If yes, how many infusions?							
Infusion 1 volume ml	Start Date	(dd/mon	/yyyy) Tim	e of Treatme	ent h h m m	(24 hour clock)	
Infusion 2 volume ml	Start Date	: (dd/mon	/yyyy) Tim	e of Treatme	ent h h : m m	(24 hour clock)	
Infusion 3 volume ml	Start Date	dd/mon	/yyyy) Tim	e of Treatme	ent h h : m m	(24 hour clock)	
Did the patient have a plasma exchange	(PE)?		Yes*	No			
*If yes, how many exchanges?							
1st Plasma Exchange		Start Date:	(dd/mon/	уууу)	Stop Date: (dd	/mon/yyyy)	
2nd Plasma Exchange		Start Date:	(dd/mon/	уууу)	Stop Date: (dd	/mon/yyyy)	
3rd Plasma Exchange		Start Date:	(dd/mon/	уууу)	Stop Date: (dd	/mon/yyyy)	
Part H(b): Red Blood Cell Transfersonest.)	usions (I	received sin	ce Random	isation and i	up to discharge/c	lay 56, whichever is	
Did the patient have a red blood cell tran	sfusion?		Yes*	No			
*If yes, how many transfusions?							
Transfusion 1 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	
Transfusion 2 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	
Transfusion 3 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	
Transfusion 4 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	
Transfusion 5 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	
Transfusion 6 volume ml/kg		Date: (dd/	mon/yyyy) Time of Tr	eatment h h :	m m (24 hour clock)	

EudraCT number:	2016-00	0997-39		Cor	ntidentia	al once com	nplete	ed	PI	ease answe	er <u>all t</u> he	questior	is 🧲
Trial Number:						[Date	of Birt	h:	/	((mon/yyy	y)
Part I (a): Re	nal Fu	nction	(betwe	en randomisa	tion an	d dischar	ge/da	ay 56, [.]	whichever	is soones	it.)		
Relevant Event	Name	Event Record	led	*If yes: Dat which deci made to s	sion	Start	t Dat	e	Stop Date (if relevant)		Dialysis Depe at Discharg		
		Yes*	No	RRT	unt						Ye	es No)
Dialysis/RRT				(dd/mon/y	ууу)	(dd/mo	on/y	ууу)	(dd/mo	n/yyyy)]
*If yes, type of F	RRT (tick	all that app	ly):	Нає	emodia	lysis		F	eritoneal		CR	RT	
If RRT stopped,	please s	tate the	reason	why below:									
Access failure				Yes	No								
No longer indica	ted			Yes	No								
Other				Yes*	No								
*If reason RRT s	stopped i	s "other"	, state	reason:									
Number of RRT	access	orocedur	es requ	uired:									
Part I (b): If a charge/day 56, v				is/RRT, pleas	e prov	vide the fo	ollov	ving va	alues (bet	ween rand	Iomisati	ion and	dis-
Lowest eGFR				ml/min/ ⁻	1.73m ²	(dd/m	non/	/уууу)					
Highest serum c	reatinine	;	[· _	µmol/	dd/m	ion/	уууу)					
Serum creatining whichever is soc		harge/da	y 56, [µmol	¹ dd/m	ion/	уууу)					
Part I (c): Oli	goanu	ria (betw	veen ra	andomisation a	and dis	charge/da	ay 56	δ, whicł	never is so	oonest.)			
Oligoanuria pos (defined as <0.5ml/k	t random <g 12<="" for="" hr="" td=""><td>isation hours)</td><td></td><td>Yes</td><td>N</td><td>• Start D</td><td>ate:</td><td>(dd/mo</td><td>n/yyyy)</td><td>Stop Date</td><td>:: (dd/m</td><td>on/yyyy</td><td>)</td></g>	isation hours)		Yes	N	• Start D	ate:	(dd/mo	n/yyyy)	Stop Date	:: (dd/m	on/yyyy)
Part J: Samp	ole Tra	cking (during	in-patient stay	. Pleas	e complet	te the	e samp	les log in	the site file	э).		
Optional/Not Optional	Samp	le		onsent option I samples?		ay 2 Samp ken?	ole	Day 4 taken	Sample ?	Day 6 Sa taken?	mple	Day 8 \$ taken?	
Optional	Blood (Neutr	ophils)		Yes	No Da	ate sample	e tak	en:	/	/		_ (dd/m	on/yyyy
Not optional	Blood geneti	EDTA— cs			Da	ate sample	e tak	en:	/	/		_ (dd/mo	n/yyyy)
Optional	Blood	(EDTA)		Yes	No	Yes	No	Ye	s No	Yes	No	Yes	
Optional	Blood culture			Yes	No	Yes	No	Ye	s 🔤 No	Yes [No	Yes	
Optional	Urine		П	Yes	No	Yes	No	Ye	s No	Yes	No	Yes	

Notes/problems with sample preparation, if any:

(Please specify which sample)

Confidential once completed

Please answer <u>all the questions</u>

2			
1	1		1
)	
5	à	 Je.	σ/

Date of Birth: ____ / ___ (mon/yyyy)

Trial Number:			

Part K: CNS Investigations Summary								
Were there any CNS investigations -	since randomisatior	1?		Yes* No				
*If yes, please enter each investigation b	pelow separately:							
Relevant Investigation Name	Investigation 1 Recorded	Investigation 2 Recorded	Investigation 3 Recorded	Investigation 4 Recorded				
EEG performed	Yes* No	Yes* No	Yes* No	Yes* No				
*If yes, give date	(dd/mon/yyyy)	(dd/mon/yyyy)	(dd/mon/yyyy)	(dd/mon/yyyy)				
*If yes, please select <u>one</u> of th	ne options below for e	each event recorded:						
No abnormal findings								
Focal abnormality in one hemisphere								
Multi-focal abnormalities confined to one hemisphere								
Multi-focal abnormalities involving both hemispheres								
Generalised abnormality with no particular focus								
Cerebral MRI performed	Yes* No	Yes* No	Yes* No	Yes* No				
*If yes, give date	(dd/mon/yyyy)	(dd/mon/yyyy)	(dd/mon/yyyy)	(dd/mon/yyyy)				
[*] If yes, please select <u>one</u> of the	e options below for ea	ch event recorded:						
No abnormal findings								
Focal abnormality in one hemisphere								
Multi-focal abnormalities confined to one hemisphere (+/- ipsilateral cerebellum):								
Multi-focal abnormalities involving both hemispheres (+/- contralateral cerebel- lum)								

Note: If neurological abnormalities are detected, book 60 day neurological assessments as per protocol

Part L: Neurological Findings (since randomisation)	Yes	No
Any Obvious CNS involvement?	*	
(*If yes, complete questions below)		
Altered consciousness (Agitation, irritability, hallucinations, confusion, excessive drowsiness)		
Single seizure		
Two or more seizures 24 hrs apart		
Transient focal neurological defect (>24 hours but <1 week)		

EudraCT number: 2016-000997-39	Confi	dential once completed	Please answer all t	he questions	
Trial Number:	mber: / (mon/yyyy)				
Part M: Pancreatic Findings (since randomisation)					
Event				Event Recorded	
Was parenteral nutrition given?				No	
*If yes, why was parenteral nutrition given? Pancreatitis Other					
Any Clinical or biochemical evidence of pancreatitis				No	
(*If yes, complete questions below)					
Raised amylase and/or lipase without clinical symptoms/signs				No	
Hyperglycaemia (non-fasting glucose ≥ 11mmol/l, fasting glucose ≥7mmol/l) without insulin requirement				No	
Pancreatitis with sequelae eg. Laparotomy, parenteral nutrition due to pancreatitis, insulin required			Yes	No	
Part N: Gastrointestinal Surgery (since randomisation)					
Event	Event recorded? Yes* No	Procedure date			
Abdominal surgery (not related to catheter insertion)					
*If yes to abdominal surgery please	e select which of the below	were required/detected			
Laparoscopy/laparotomy		(dd/mon/yyyy)			
Intestinal perforation AND/OR bowel resection		(dd/mon/yyyy)			
Stoma formation		(dd/mon/yyyy)			
Part O: Cardiac Findings (since randomisation)					
Event				Event Recorded? Yes No	
Any Cardiac Involvement (normal CVS examination—except hypertension/volume overload)					
(*If yes, complete questions below)					
Cardiac failure confirmed by ECHO (impaired systolic ventricular function or chamber enlargement or valve regurgitation)					
Cardiac failure confirmed by ECHO with dilated cardiomyopathy					
Myocardial infarction (on standard ECG +/- troponin +/- ECHO evidence)					
Part P: Form Completion					
Completed by (name):					
Signed:Date Completed: (dd/mon/yyyy)					
PI Name:					
PI Confirmation Signature: Date Completed: (dd/mon/yyyy)					